GLP-1 drugs show limited effects on mental health and life outcomes
A study from the University of Chicago found that GLP-1 medications like Ozempic improve blood sugar, weight, and cardiovascular health, but showed little evidence of improving mental health, employment, marriage, or overall well-being. The broader life effects may be subtler than the dramatic physical benefits.
The study tracked adults with diabetes over a decade using Medical Expenditure Panel Survey data, following the same individuals before and after starting GLP-1 treatment. Initial gaps between users and non-users in employment and marriage disappeared when researchers examined within-person changes over time, suggesting these differences reflected who chooses the drugs rather than drug effects. Results held at both one-year and two-year follow-ups.
Researchers note their measures—employment, marital status, standard mental health indicators—may miss subtler shifts in self-esteem or relationship quality. This matters as insurers and government programs weigh broader GLP-1 coverage, where evidence of social or economic gains could strengthen the case for wider access.
This research could influence coverage decisions by insurers and government programs weighing whether GLP-1 drugs justify broader access. If the medications primarily deliver physical health benefits without measurable social or economic gains, policymakers may focus arguments for expanded coverage on medical outcomes rather than broader life improvements. Patients considering these drugs may also recalibrate expectations, understanding that weight loss and cardiovascular gains don't automatically translate into better mental health or relationship outcomes. The findings could temper enthusiasm about the drugs' transformative potential beyond the body.